Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

NCT04377620 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

211

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated by sponsor

Conditions

COVID-19

Interventions

DRUG: Placebo
DRUG: Ruxolitinib

Sponsor

Incyte Corporation